Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
World game at war: why some European nations have threatened a World Cup boycott 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
